Paroxetine-induced severe sleep bruxism successfully treated with buspirone

Milanlıoğlu, Aysel

doi:10.6061/clinics/2012(02)17

Cited by 28 publications

(15 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 Three articles reported alleviation of symptoms with cessation of the offending agent in combination with buspirone therapy. [11][12][13] One case reported spontaneous resolution of symptoms without any interventions. 14 In the above articles, buspirone dosage typically ranged between 5 and 30 mg administered in 1-3 doses per day.…”

Section: Resultsmentioning

confidence: 99%

SSRI-associated bruxism

Garrett

Hawley

2018

Neur Clin Pract

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

SSRI-associated bruxism

Garrett

Hawley

2018

Neur Clin Pract

View full text Add to dashboard Cite

show abstract

“…Consensus decision was to exclude 12 of the 26 papers. Reasons for exclusion were the following: single case reports of patients treated for bruxism not diagnosed with PSG or EMG ( N = 4) ; case series of cohorts of patients treated for bruxism not diagnosed with PSG or EMG ( N = 4) ; studies with an absence of criteria that were used for scoring SB activity ( N = 3) ; and a survey paper ( N = 1) . Thus, fourteen papers were included in the review.…”

Section: Resultsmentioning

confidence: 99%

Management of sleep bruxism in adults: a qualitative systematic literature review

Manfredini

Ahlberg

Winocur

et al. 2015

J of Oral Rehabilitation

150

126

View full text Add to dashboard Cite

This paper updates the bruxism management review published by Lobbezoo et al. in 2008 (J Oral Rehabil 2008; 35: 509-23). The review focuses on the most recent literature on management of sleep bruxism (SB) in adults, as diagnosed with polysomnography (PSG) with audio-video (AV) recordings, or with any other approach measuring the sleep-time masticatory muscles' activity, viz., PSG without AV recordings or electromyography (EMG) recorded with portable devices. Fourteen (N = 14) papers were included in the review, of which 12 were randomised controlled trials (RCTs) and 2 were uncontrolled before-after studies. Structured reading of the included articles showed a high variability of topics, designs and findings. On average, the risk of bias for RCTs was low-to-unclear, whilst the before-after studies had several methodological limitations. The studies' results suggest that (i) almost every type of oral appliance (OA) (seven papers) is somehow effective to reduce SB activity, with a potentially higher decrease for devices providing large extent of mandibular advancement; (ii) all tested pharmacological approaches [i.e. botulinum toxin (two papers), clonazepam (one paper) and clonidine (one paper)] may reduce SB with respect to placebo; (iii) the potential benefit of biofeedback (BF) and cognitive-behavioural (CB) approaches to SB management is not fully supported (two papers); and (iv) the only investigation providing an electrical stimulus to the masseter muscle supports its effectiveness to reduce SB. It can be concluded that there is not enough evidence to define a standard of reference approach for SB treatment, except for the use of OA. Future studies on the indications for SB treatment are recommended.

show abstract

“…Although some antidepressants have the ability to induce sleep, improving this cycle and reduce orofacial pain, these medications increase the ability of individuals to develop bruxism, or significantly increase this habit in people who have already has 18 . The use of paroxetine, venlafaxine and duloxetine was more likely to be associated with the development of bruxism 19 . Therefore, physicians should always report to patients about possible adverse effects during their prescription, particularly inhibitors of paroxetine and serotonin reuptake and norepinephrine 18,19 .…”

Section: Discussionmentioning

confidence: 96%